DiaMedica identifies cause of DM199 clinical hold; plans FDA resubmission in Sep

DiaMedica Therapeutics Inc.

Clinical hold cause: DM199 protein bound to prior IV bag, reducing dose; new bag delivered higher dose, causing hypotension.
Will submit revised protocol to FDA in September requesting removal of clinical hold; FDA has 30 days to respond.
Cash and investments $38.4M as of June 30, 2022; cash runway into 2024.
R&D expenses $2.0M in Q2 2022 vs $2.2M Q2 2021; net cash used in ops $6.4M for six months.
REDUX CKD trial close-out ongoing; company maintains focus on acute ischemic stroke program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.